Jika pengobatan baru efektif dalam sebuah studi, ia dapat dijadikan pengobatan standar yang dapat menolong banyak pasien. Umumnya pengobatan standar yang paling efektif sekarang ini berdasarkan pada hasil studi sebelumnya, seperti pada kanker payudara, kolon, rektal dan kanker yang menyerang pada anak-anak.

Pasien yang berpartisipasi dapat terbantu dengan sendirinya melalui pengobatan yang mereka terima. Peserta uji coba mendapatkan pengobatan terbaru dari spesialis kanker dan mereka memperoleh baik pengobatan baru yang telah diuji atau pengobatan standar terbaik yang tersedia untuk kanker yang diderita.

Tidak terdapat jaminan bahwa pengobatan baru yang telah diuji coba tidak akan menimbulkan efek samping ataupun akan memberikan hasil yang baik. Jika pengobatan baru terbukti efektif atau lebih efektif daripada pengobatan standar, peserta uji coba klinis inilah yang pertama merasakan manfaatnya.

Meskipun studi penelitian sangat penting bagi kemajuan pengobatan, pusat penelitian Rumah Sakit Beacon mengutamakan hak, keamanan dan kesejahteraan pasien yang terlibat dalam uji coba klinis. Terlepas dari kenyataan bahwa semua studi klinis kami telah mendapatkan persetujuan dari komite etika medis dan penelitian Kementerian Kesehatan Malaysia, kami juga mematuhi standar praktik klinis local atau internasional yang baik untuk menjaga kepentingan etis pasien uji coba klinis.

Hingga kini, tim onkologi kami telah berpartisipasi dalam berbagai uji coba klinis termasuk membandingkan efektivitas pengobatan kemoterapi yang berbeda; resistansi penghambat; perubahan epigenetik pada kanker nasofaring; dan pengobatan untuk adenocarcinoma pada persimpangan gastroesofagus stadium lanjut atau metastatik.

No	Judul Protokol	Status
1	MS200095-0031-INSIGHT 2 A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplifies, advanced or metastatic non-small cell lung cancer(NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy.	Aktif (Merekrut)
2	ATORG 001 A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).	Aktif (Merekrut)
3	MK7902-007 A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).	Aktif (Merekrut)
4	CT-P16 3.1 A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.	Aktif (Merekrut)
5	A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer	Aktif (Berhenti merekrut)
6	MK3475-394 A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma	Aktif (Berhenti merekrut)
7	Keynote-590 A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5-fluorouracil versus placebo in combination with cisplatin and 5-fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma	Aktif (Berhenti merekrut)
8	Tessa FF01: A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC	Aktif (Berhenti merekrut)
9	MK3475-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)	Aktif (Berhenti merekrut)
10	CLEE011A2404 An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Aktif (Berhenti merekrut)
11	EMR200095-006 Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor	Aktif (Berhenti merekrut)
12	CT10-01 Malaysian Cell Therapy Patient Registry: A Patient Registry (clinical database) to Evaluate the Health Outcomes of Patients who had received Cell Therapy In Malaysia	Mendatang (Tinjauan protokol)
13	Studies On Epigenetic Changes In Nasopharyngeal Cancer	Selesai
14	Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care	Selesai
15	Healthcare Performance Measurement And Reporting For Breast Cancer Services In Malaysia	Selesai(View abstract) (View paper)
16	A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma	Selesai
17	A Randomized, 3 Arm, Multicentre, Phase III Study To Evaluate	Selesai
18	A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.	Selesai
19	An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)	Selesai

Terlepas dari uji coba klinis onkologi, konsultan kami dari pusat-pusat keunggulan lainnya juga memberikan kontribusi pada spesialisasi klinis mereka dengan penelitian mereka yang dipublikasikan.

No	Judul Publikasi	Nama Konsultan	Jenis Presentasi
1	Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs	Dr Ong Chin Tuan (Consultant Ophthalmologist)	Poster

Jika anda tertarik dan ingin mengetahui lebih lanjut mengenai uji coba klinis yang sedang berlangsung, silahkan hubungi kami di  +603 7787 2854 atau anda dapat mengirim email pada kami di clinicalresearch@beaconhospital.com.my.

Search For Consultant